Browse > Article
http://dx.doi.org/10.22156/CS4SMB.2020.10.12.146

Evaluation of Clinical Usefulness of Gamma Glutamyl Transferase as a Surrogate Marker for Metabolic Syndrome in Non Obese Adult Men  

Shin, Kyung-A (Dept. of Clinical Laboratory Science, Shinsung University)
Kim, Eun Jae (Dept. of Obstetrics and Gynecology, Seoul National University)
Publication Information
Journal of Convergence for Information Technology / v.10, no.12, 2020 , pp. 146-155 More about this Journal
Abstract
This study was to evaluate the usefulness of gamma glutamyl transferase (GGT) as a surrogate marker predicting metabolic syndrome. 7,155 non obese men over the age of 20 were studied as subjects. The criteria for diagnosing MetS were the National Cholesterol Education Program - Third Adult Treatment Panel (NCEP-ATP III). The risk of developing MetS according to GGT was conducted logistic regression analysis, and the ROC (receiver operating characteristic) curve was obtained to confirm GGT ability to predict the risk of MetS. Regardless of age and body mass index, MetS had a 7.09 times higher risk of onset in the fourth quartile than in the first quartile of GGT (p<0.001). The AUC (area under the curve) of GGT for the diagnosis of MetS was 0.715, and the cutoff value of GGT was 40.0 U/L, the sensitivity was 65.0%, and the specificity was 70.2%. Therefore, GGT is considered to be a useful diagnostic index for diagnosing MetS.
Keywords
Liver Enzyme; Gamma Glutamyl Transferase; Surrogate Marker; Metabolic Syndrome; Clinical Usefulness;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). The Journal of the American Medical Association, 285(19), 2486-2497. DOI : 10.1001/jama.285.19.2486   DOI
2 D. S. Lee et al. (2007). Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(1), 127-133. DOI : 10.1161/01.ATV.0000251993.20372.40   DOI
3 G. Ndrepepa & A. Kastrati. (2016). Gamma-glutamyl transferase and cardiovascular disease. Annals of Translational Medicine, 4(24), 481. DOI : 10.21037/atm.2016.12.27   DOI
4 J. B. Whitfield. (2001). Gamma glutamyl transferase. Critical Reviews in Clinical Laboratory Sciences, 38(4), 263-355. DOI : 10.1080/20014091084227   DOI
5 G. Wannamethee, S. Ebrahim & A. G. Shaper. (1995). Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. American Journal of Epidemiology, 142(7), 699-708. DOI : 10.1093/oxfordjournals.aje.a117699   DOI
6 D. J. Kim et al. (2005). Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabetic Medicine, 22(9), 1134-1140. DOI : 10.1111/j.1464-5491.2005.01581.x   DOI
7 I. Abete, E. Goyenechea, M. A. Zulet & J. A. Martinez. (2011). Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutrition, Metabolism & Cardiovascular Diseases, 21(Suppl 2), B1-B15. DOI : 10.1016/j.numecd.2011.05.001   DOI
8 Y. Xu et al. (2011). Cross-sectional and longitudinal association of serum alanine aminotransaminase and γ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. Journal of Diabetes, 3(1), 38-47. DOI : 10.1111/j.1753-0407.2010.00111.x   DOI
9 A. C. Hwang, Y. C. Lin, P. T. Liu, Y. M. Kao & J. D. Chen. (2012). Synergistic effect of gamma glutamyltransferase and obesity on metabolic syndrome, independent of hepatic steatosis. Annals of Epidemiology, 22(12), 876-880. DOI : 10.1016/j.annepidem.2012.09.012   DOI
10 M. Y. Lee et al. (2008). Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. Diabetic Medicine, 25(4), 469-475. DOI : 10.1111/j.1464-5491.2008.02415.x   DOI
11 O. Niemela. (2016). Biomarker-Based Approaches for Assessing Alcohol Use Disorders. International Journal of Environmental Research and Public Health, 13(2), 166. DOI : 10.3390/ijerph13020166   DOI
12 K. A. Shin. (2019). Comparison of the serum gamma-glutamyl transferase and serum uric acid levels according to the obesity types based upon on the body mass index in Korean men. Korean Journal of Clinical Laboratory Science, 51(1), 50-56. DOI : 10.15324/kjcls.2019.51.1.50   DOI
13 M. Penke, W. Kiess & T. Giorgis. (2016). Non-alcoholic fatty liver disease in children and adolescents. Journal of Pediatric Endocrinology and Metabolism, 29(12), 1329-1330. DOI : 10.1515/jpem-2016-0415   DOI
14 M. Boyraz et al. (2014). Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obesity Research and Clinical Practice, 8(4), e356-e363. DOI : 10.1016/j.orcp.2013.08.003   DOI
15 V. Regitz-Zagrosek, E. Lehmkuhl & M. O. Weickert. (2006). Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clinical Research in Cardiology, 95(3), 136-147. DOI : 10.1007/s00392-006-0351-5   DOI
16 M. Tiikkainen et al. (2002). Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obesity Research, 10(9), 859-867. DOI : 10.1038/oby.2002.118   DOI
17 C. K. Roberts, R. J. Barnard, R. K. Sindhu, M. Jurczak, A. Ehdaie & N. D. Vaziri. (2006). Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism, 55(7), 928-934. DOI : 10.1016/j.metabol.2006.02.022   DOI
18 E. M. Alissa. (2018). Relationship between serum gamma-glutamyltransferase activity and cardiometabolic risk factors in metabolic syndrome. Journal of Family Medicine and Primary Care, 7(2), 430-434. DOI : 10.4103/jfmpc.jfmpc_194_17   DOI
19 D. E. Laaksonen, H. M. Lakka, L. K. Niskanen, G. A. Kaplan, J. T. Salonen & T. A. Lakka. (2002). Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. American Journal of Epidemiology, 156(11), 1070-1077. DOI : 10.1093/aje/kwf145   DOI
20 B. Isomaa et al. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24(4), 683-689. DOI : 10.2337/diacare.24.4.683   DOI
21 J. Lu et al. (2017). Metabolic Syndrome Among Adults in China: The 2010 China Noncommunicable Disease Surveillance. Journal of Clinical Endocrinology and Metabolism, 102(2), 507-515. DOI : 10.1210/jc.2016-2477   DOI
22 K. Lee, J. Han & S. G. Kim. (2014). Increasing risk of diabetes mellitus according to liver function alterations in electronic workers. Journal of Diabetes Investigation, 5(6), 671-676. DOI : 10.1111/jdi.12202   DOI
23 M. Adiels et al. (2006). Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia, 49(4), 755-765. DOI : 10.1007/s00125-005-0125-z   DOI
24 D. H. Lee, R. Blomhoff & D. R. Jacobs. (2004). Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radical Research, 38(6), 535-539. DOI : 10.1080/10715760410001694026   DOI
25 P. M. Ridker, P. W. F. Wilson & S. M. Grundy. (2004). Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation, 109(23), 2818-2825. DOI : 10.1161/01.CIR.0000132467.45278.59   DOI
26 I. Lemieux et al. (2001). Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 21(6), 961-967. DOI : 10.1161/01.atv.21.6.961   DOI
27 A. Kerner et al. (2005). Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(1), 193-197. DOI : 10.1161/01.ATV.0000148324.63685.6a   DOI
28 J. M. Park, J. Y. Lee, D. C. Lee & Y. J. Lee. (2017). Serum γ-glutamyltransferase level and metabolic syndrome in children and adolescents: Korean National Health and Nutrition Examination Survey. Journal of Diabetes Investigation, 9(3), 522-528. DOI : 10.1111/jdi.12716   DOI
29 B. Kasapoglu, C. Turkay, Y. Bayram & C. Koca. (2010). Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian Journal of Medical Research, 132, 56-61.
30 S. Lee et al. (2015). Serum gamma-glutamyltransferase levels are associated with concomitant cardiovascular risk factors in Korean hypertensive patients: A nationwide population-based study. Medicine (Baltimore), 94(50), e2171. DOI : 10.1097/MD.0000000000002171   DOI
31 G. Marchesini & G. Forlani. (2002). NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology, 35(2), 497-499. DOI : 10.1053/jhep.2002.31551   DOI
32 B. S. Suh. (2012). The association between serum gamma-glutamyltransferase within normal levels and metabolic syndrome in office workers: A 4-year follow-up study. Korean Journal of Family Medicine, 33(1), 51-58. DOI : 10.4082/kjfm.2012.33.1.51   DOI
33 D. Z. Banderas, J. Escobedo, E. Gonzalez, M. G. Liceaga, J. C. Ramirez & M. G. Castro. (2012). γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. European Journal of Gastroenterology & Hepatology, 24(7), 805-810. DOI : 10.1097/MEG.0b013e328354044a   DOI
34 R. A. DeFronzo & E. Ferrannini. (1991). Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14(3), 173-194. DOI :10.2337/diacare.14.3.173   DOI
35 G. Erkan, I. Sayin, F. B. Polat, A. Corakci, G. K. Atac & H. Degertekin. (2014). The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study. Turkish Journal of Gastroenterology, 25(Suppl 1), 63-68. DOI : 10.5152/tjg.2014.6233   DOI
36 K. Lee & J. H. Yang. (2013). Which liver enzymes are better indicators of metabolic syndrome in adolescents: the Fifth Korea National Health and Nutrition Examination Survey, 2010. Metabolic Syndrome and Related Disorders, 11(4), 229-235. DOI : 10.1089/met.2012.0153   DOI
37 World Health Organization. (2000). The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia.
38 J. Hung, B. M. McQuillan, P. L. Thompson & J. P. Beilby. (2008). Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. International Journal of Obesity (Lond), 32(5), 772-779. DOI : 10.1038/sj.ijo.0803793   DOI
39 J. Lugrin, N. Rosenblatt-Velin, R. Parapanov & L. Liaudet. (2014). The role of oxidative stress during inflammatory processes. Biological Chemistry, 395(2), 203-230. DOI : 10.1515/hsz-2013-0241   DOI
40 M. Hamaguchi et al. (2005). The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of Internal Medicine, 143(10), 722-728. DOI : 10.7326/0003-4819-143-10-200511150-00009   DOI
41 M. Franzini et al. (2017). Association between plasma gamma-glutamyltransferase fractions and metabolic syndrome among hypertensive patients. Scientific Reports, 7(1), 12003. DOI : 10.1038/s41598-017-12356-w   DOI
42 M. Lafontan & N. Viguerie. (2006). Role of adipokines in the control of energy metabolism: focus on adiponectin. Current Opinion in Pharmacology, 6(6), 580-585. DOI :10.1016/j.coph.2006.08.002   DOI
43 L. Tao et al. (2013). Association between γ-glutamyl transferase and metabolic syndrome: a cross-sectional study of an adult population in Beijing. International Journal of Environmental Research and Public Health, 10(11), 5523-5540. DOI : 10.3390/ijerph10115523   DOI
44 Y. H. Kang, H. K. Min, S. M. Son, I. J. Kim & Y. K. Kim. (2007). The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Research and Clinical Practice, 77(2), 306-313. DOI : 10.1016/j.diabres.2006.11.009   DOI